Australian biotech company Noxopharm is scaling up production of its preclinical SOF-SKN lupus medication to the quality standards that will be required for upcoming regulatory submissions.
Australian biotech firm Noxopharm has announced that the Victorian Government has granted A$1.45M to Noxopharm collaborator, Hudson Institute of Medical Research to fund the joint development programme of novel anti-inflammatory compounds.
SYDNEY--(BUSINESS WIRE)--Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda®, its lead oncology drug candidate, for use in the treatment of soft tissue sarcoma.
Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los Angeles, California.
The Noxopharm Ltd (ASX: NOX) share price is on the rise today after a clinical trial update.
SYDNEY--(BUSINESS WIRE)--Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research. The exclusive global contract aims to maximize opportunities in RNA drug discovery and mRNA vaccine manufacture through Noxopharm’s wholly owned subsidiary, Pharmorage.
SYDNEY--(BUSINESS WIRE)--Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its DARRT-2 Phase 2 clinical trial has commenced with patient enrollment in the U.S.
SYDNEY - ( BUSINESS WIRE ) - Australian clinical-stage drug development company Noxopharm (ASX: NOX) has released the first preliminary data from its phase I clinical trial NOXCOVID, which assesses the suitability of idronoxil ( Veyonda ® ), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with a moderate form of COVID-19. Based on the first positive results, Noxopharm has initiated discussions to integrate Veyonda into one of the global clinical trial programs aimed at identifying effective anti-inflammatory treatments for COVID-19.
SYDNEY--(BUSINESS WIRE)--Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer. This result validates the survival benefit of the same combination seen in a recently completed Phase I/II trial of Veyonda in men with end-stage metastatic castrate-resistant prostate cancer (mCRPC).
The clinical-stage drug development company will team up with an arm of the National Institutes of Health as it investigates a new family of anti-cancer drugs.